West Pharmaceutical Services (WST) EBT (2009 - 2026)

West Pharmaceutical Services has disclosed EBT across 18 years of filings, most recently posting $180.1 million for Q1 2026.

• EBT for Q1 2026 came in at $180.1 million, up 62.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $670.5 million (up 17.92% YoY), and the FY2025 annual result was $600.9 million, up 2.63% from the prior year.
• EBT came in at $180.1 million for Q1 2026 at West Pharmaceutical Services, up from $161.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $227.2 million in Q2 2022 to a low of $110.5 million in Q1 2025.
• The 5-year median for EBT is $164.5 million (2024), against an average of $161.4 million.
• Across the five-year window, EBT slumped 30.39% in 2024 and surged 62.99% in 2026, its largest moves.
• West Pharmaceutical Services' EBT stood at $128.7 million in 2022, then soared by 30.69% to $168.2 million in 2023, then dropped by 1.96% to $164.9 million in 2024, then decreased by 2.06% to $161.5 million in 2025, then gained by 11.52% to $180.1 million in 2026.
• The last three EBT figures came in at $180.1 million (Q1 2026), $161.5 million (Q4 2025), and $171.9 million (Q3 2025), per Business Quant data.